Bladder Cancer Clinical Trial

Tesetaxel for Previously Treated Patients With Bladder Cancer

Summary

The intravenously administered taxanes, docetaxel and paclitaxel, alone and in combination with other chemotherapy agents are active in patients with advanced and metastatic bladder cancer, and agents of this class are a promising treatment option for some patients.

Tesetaxel is an orally administered taxane that is in development as treatment for subjects with advanced cancers. This study is being conducted to determine the efficacy and safety of tesetaxel administered to patients previously treated with chemotherapy for progressive metastatic transitional cell carcinoma of the urothelium.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

At least 18 years of age
Histologically confirmed diagnosis of urothelial carcinoma of the bladder, urethra, ureter, or renal pelvis
Measurable disease (revised RECIST; Version 1.1)
Karnofsky performance status ≥ 60%
Previously treated with not more than 1 doublet or triplet regimen and that regimen contained gemcitabine and a platinum agent
Adequate bone marrow, hepatic, and renal function, as specified in the protocol
At least 4 weeks and recovery from effects of prior surgery, prior radiotherapy, or other therapy with an approved or investigational agent
Ability to swallow an oral solid-dosage form of medication

Exclusion Criteria:

Known metastasis or symptoms of metastasis to the central nervous system
Significant medical disease other than cancer
Presence of neuropathy > Grade 1 (NCI CTC, Version 4.0)
Prior treatment with a taxane or other tubulin-targeted agent (eg, indibulin) other than a vinca alkaloid
Need to continue any regularly-taken medication that is a potent inhibitor or inducer of the CYP3A pathway or P-glycoprotein activity

Study is for people with:

Bladder Cancer

Phase:

Phase 2

Estimated Enrollment:

33

Study ID:

NCT01215877

Recruitment Status:

Unknown status

Sponsor:

Genta Incorporated

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 3 Locations for this study

See Locations Near You

Memorial Sloan-Kettering Cancer Center
New York New York, 10065, United States More Info
Dean F Bajorin, MD
Contact
646-422-4333
Dean F Bajorin, MD
Principal Investigator
Thomas Jefferson University Hospital
Philadelphia Pennsylvania, 19107, United States More Info
Deborah Kilpatrick
Contact
215-955-0017
[email protected]
Jean Hoffman-Censits, MD
Principal Investigator
San Camillo Forlanini Hospital
Rome , 00152, Italy More Info
Cora N Sternberg, MD, FACP
Contact
[email protected]
Cora N Sternberg, MD, FACP
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Phase:

Phase 2

Estimated Enrollment:

33

Study ID:

NCT01215877

Recruitment Status:

Unknown status

Sponsor:


Genta Incorporated

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider